Calithera Biosciences Inc Up 180 For Week On Drug Data, Licence Pact

Calithera Biosciences Inc. (NASDAQ: CALA) closed Friday up more than 180 percent during the week after the company issued promising pre-clinical data about a lead drug candidate.Calithera told investors Monday its cancer treatment CB-839 showed "significant anti-tumor efficacy" in a preclinical study.The data was presented at the American Society of Hematology meeting in San Francisco, where the company also offered promising interim results from a Phase I clinical study of the drug in treating breast cancer.Separately, on Tuesday, Calithera said it obtained a license from Mars Inc.'s Symbioscience unit on a preclinical arginase inhibitor program.Calithera said the deal will boost it's efforts to submit an Investigational New Drug application for a cancer treatment with the FDA near the end of 2015. Calithera closed Friday at $29.85 a share, up $6.65 during the day.